— Patency and host cell remodeling of the HAV were observed in all study implants – — Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application – DURHAM, N.C., Nov. […]
Tag: Humacyte
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights
— Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds — — Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications — DURHAM, N.C., Nov. 12, 2021 […]
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
Humacyte raises $245M gross proceeds Combined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021 Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications […]
Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte
NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) — Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a […]
Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs
Appoints proven commercial leader B.J. Scheessele as Chief Commercial Officer In-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing system Company’s proprietary modular manufacturing systems can produce an estimated 40,000+ vessels annually in current […]
Humacyte Appoints Dale Sander as Chief Financial Officer
Proven CFO with extensive financial leadership and commercialization experience, including multiple publicly listed life sciences companies DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, […]
Humacyte Secures $50 Million Debt Facility with Silicon Valley Bank
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the closing of a secured debt financing facility with Silicon Valley Bank for up […]
Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson MD, PhD has been appointed President and Chief Executive Officer. Carrie S. Cox has assumed the role of Executive Chairman. Dr. Lawson, an […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet